VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) program through a collaboration with ATUM. The partnership will leverage ATUM’s Leap-In Transposase technology to generate stable clonal cell lines that support Investigational New Drug (IND) and Clinical Trial Application (CTA)-enabling activities, as well as future clinical development.

The announcement follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The cell line development is intended to support chemistry, manufacturing, and controls (CMC) development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.

VERAXA’s BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.

The collaboration with ATUM is a key step in advancing the BiTAC-TCE program toward clinical trials. By establishing stable cell lines early, VERAXA aims to streamline the development process and ensure a reliable supply of material for regulatory studies. The company’s focus on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, underscores its commitment to innovative cancer treatments.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company’s proprietary BiTAC format is a registered trademark of VERAXA Biotech GmbH. For more information, visit the company’s newsroom at https://ibn.fm/VRXA and the full press release at https://ibn.fm/FCIlk.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy.

The post VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy appeared first on citybuzz.